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Some viruses display enhanced infection for Fc receptor (FcR)-positive cell types when complexed with virus-specific immunoglobulin
(Ig). This process has been termed antibody-dependent enhancement of viral infection (ADE). We reasoned that the mechanism of ADE
could be exploited and adapted to target alphavirus-based vectors to FcR-positive cell types. Towards this goal, recombinant Sindbis viruses
were constructed that express 1 to 4 immunoglobulin-binding domains of protein L (PpL) as N-terminal extensions of the E2 glycoprotein.
PpL is a bacterial protein that binds the variable region of antibody kappa light chains from a range of mammalian species. The recombinant
viruses incorporated PpL/E2 fusion proteins into the virion structure and recapitulated the species-specific Ig-binding phenotypes of native
PpL. Virions reacted with non-immune serum or purified IgG displayed enhanced binding and ADE for several species-matched FcR-
positive murine and human cell lines. ADE required virus expression of a functional PpL Ig-binding domain, and appeared to be FcgR-
mediated. Specifically, ADE did not occur with FcgR-negative cells, did not require active complement proteins, and did not occur on FcgR-
positive murine cell lines when virions were bound by murine IgG-derived F(abV)2 fragments.
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Alphaviruses are single-stranded, positive-sense RNA
viruses, and are classified within the Togaviridae virus
family (genus Alphavirus) (Strauss and Strauss, 1994). The
alphavirus genome can accommodate foreign gene sequen-
ces and a variety of recombinant alphavirus-based expres-
sion vectors have been described (Frolov et al., 1996;
Rayner et al., 2002; Ryman et al., 2004; Schlesinger and
Dubensky, 1999; Thomas et al., 2003). Alphaviruses display
tropisms for a broad range of cell/tissue types in vivo, and
alphavirus-based vectors have been used for targeted trans-
gene expression in dendritic cells (DCs) (Gardner et al.,
2000; Ryman et al., 2002) neurons (Altman-Hamamdzic
et al., 1997; van Marle et al., 2003), vascular smooth muscle
(Roks et al., 2002), and tumors (Tseng et al., 2002, 2003).0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.04.039
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E-mail address: hans.heidner@utsa.edu (H.W. Heidner).However, targeting alphavirus vectors to cell/tissue types
not included in their natural viral tropism is more difficult as
this requires strategies for ablating or minimizing the natural
tropism of the virus, and for generating the desired tropism
de novo. Dubuisson and Rice (Dubuisson and Rice, 1993)
demonstrated that the normal receptor-binding properties of
Sindbis virus could be disrupted by the insertion of short
peptides (11 amino acids) into defined regions of the PE2
glycoprotein. Viruses containing these modifications dis-
played markedly reduced binding to CEF and BHK-21 cells,
but retained all other replication functions. Efforts to
redirect the cell/tissue tropism of alphaviruses have focused
on generating novel virus affinities for specific receptors
expressed on the surface of target cells. One approach has
been to incorporate a receptor-specific ligand into the
Sindbis virus E2 glycoprotein (Sawai and Meruelo, 1998).
An alternative approach utilized receptor-specific antibodies
as a bridge to link Sindbis virus-based replicons to receptors
on target cells. This strategy involved insertion of an IgG-005) 9 – 21
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the E2 glycoprotein, followed by formation of a replicon/
IgG complex via interactions between the protein A domain
and the Fc region of IgG. By design, the cell type that is
targeted by the replicon particle/IgG complex is determined
by the Fab regions of the immunoglobulin (Ig) molecule,
which should be specific for a surface antigen that is
expressed by the cell type of interest. Although replicon
particles containing the receptor-specific ligand or protein A
domain could be targeted to specific cell types in cell
culture, the particles exhibited low infectious titer and
appeared to exclude E1 from their structure (Iijima et al.,
1999; Ohno et al., 1997; Sawai and Meruelo, 1998).
The objective of this project was to develop a new
strategy for targeting alphaviruses and alphavirus-based
replicon particles to cell types that express receptors for the
Fc region of certain classes of Ig. Many cells of myeloid or
lymphoid origin express FcRs that bind to the Fc region of
IgG (FcgR), or other classes of Ig (Ravetch and Bolland,
2001). FcR-positive cells are able to capture microbes/
antigens that are bound by Ig (immune complexes [ICs]),
and for some cell types, including macrophages and DCs,
this interaction can lead to internalization of the IC/FcR
complex. IgG-bound virions can also interact with FcgRs,
and a variety of viruses have been shown to exploit the
FcgR-mediated endocytic pathway to infect FcgR-positive
cells. This phenomenon is known as antibody-dependent
enhancement of viral infection (ADE) (Takada and
Kawaoka, 2003), and has been demonstrated for several
alphaviruses (Chanas et al., 1982; Lidbury and Mahalingam,
2000; Linn et al., 1996), including Sindbis virus.
We reasoned that an adaptation of the ADE mechanism
could be exploited to target alphavirus-based vectors to FcR-
positive cell types. The ability to target gene expression to
select FcR-positive cell types (e.g., DCs, macrophages, M
cells, NK cells, mast cells) could facilitate the study of these
cells, and could potentially be manipulated to enhance the
efficacy of alphavirus-based vaccine vectors. Towards this
goal we constructed Sindbis viruses that were designed to
spontaneously bind IgG in an antigen-independent manner.
This phenotype was achieved by exploiting the biological
properties of protein L (PpL). PpL is an Ig-binding, cell wall
protein expressed by the Peptostreptococcus magnus bacte-
rium (Kastern et al., 1990; Myhre and Erntell, 1985). PpL
contains 4 or 5 (depending of strain) highly homologous,
repeated Ig-binding domains (designated B1–B5), 72 to 76
amino acids in length (Kastern et al., 1992; Murphy et al.,
1994). Individual B domains possess 2 separate Ig-binding
sites; a high-affinity binding site designated site 1, and a
low-affinity binding site designated site 2 (Graille et al.,
2001, 2002; Housden et al., 2004). The Ig-binding
properties of PpL are distinctly different from those of
protein A (derived from Staphylococcus aureus) (For-
sgren and Sjo¨quist, 1966) and protein G (derived from
group C and G Streptococci) (Bjo¨rck and Kronvall, 1984;
Reis et al., 1984), which predominantly bind to the Fcregion of IgG. PpL binds with high affinity to the frame-
work region of the variable domain of kappa (human
subgroups nI, nIII, and nIV) light chains (VL) (Enokizono et
al., 1997; Nilson et al., 1992). Therefore, PpL binds Ig
independently of its class or antigen-specificity (A˚kerstro¨m
and Bjo¨rck, 1989; Bjo¨rck, 1988). PpL binds Igs from a
broad range of mammalian species, and displays particularly
high affinity for Ig derived from human and non-human
primates, mice, rats, and swine (De Chaˆteau et al., 1993).
The majority of human and murine Igs contain kappa light
chains (Nilson et al., 1993; Solomon, 1976), and PpL is able
to bind 50% or more of the polyclonal antibodies in human
serum, and at least 40% of the antibodies present in mouse
serum (Nilson et al., 1993).
In this report, we describe the construction and characteri-
zation of recombinant Sindbis viruses that express fusion
proteins consisting of 1 to 4 PpL B domains with a novel
location as N-terminal extensions of the viral E2 glycopro-
tein. E2 forms heterodimers with the second viral glyco-
protein, designated E1, and each of the 80 spike structures
that project from the surface of an alphavirus particle are
composed of three E1/E2 heterodimers (Strauss and Strauss,
1994). The recombinant viruses incorporate the PpL/E2
fusion proteins into the virion structure, bind Ig in an
antigen-independent manner, and recapitulate the species-
specific Ig-binding phenotypes of native PpL. The Ig-
binding viruses displayed FcgR-dependent ADE for several
FcgR-positive murine and human cell lines. ADE was only
demonstrated for viruses that expressed a functional PpL Ig-
binding domain, and only occurred in the presence of intact
Igs containing functional IgG Fc components.Results and discussion
Recombinant viruses contain PpL/E2 fusion proteins and
are viable
Targeting viral vectors to cell types that lie outside of
their natural tropism usually requires physical alteration of
the virus. Alterations can consist of pseudotyping virions
with glycoproteins from heterologous viruses, or inserting
receptor-specific ligands or single-chain antibodies into the
viral receptor-binding proteins. These strategies have been
applied most successfully using retrovirus- and adenovirus-
based systems (Krasnykh et al., 2000; Sandrin et al., 2003;
Wickham, 2003) for recent reviews. Sindbis virus has been
shown to tolerate the insertion of short peptides (11 amino
acids) within defined regions of the E3 and E2 proteins
(Dubuisson and Rice, 1993; London et al., 1992); however,
virus particles containing larger insertions within E2 were of
low infectivity and failed to incorporate E1 into their
structures (Ohno et al., 1997; Sawai and Meruelo, 1998).
For this study, recombinant Sindbis viruses were cons-
tructed which expressed PpL/E2 fusion proteins containing
1, 2, 3, or 4 B domains of PpL as N-terminal extensions of
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background of Sindbis virus strain TRSB-E2S1 (E2S1)
(Heidner and Johnston, 1994), and the recombinant viruses
were designated L1, L2, L3, and L4, respectively. The
decision to insert PpL sequences into this site was based on
structural data which suggests that the E3 region of PE2-
cleavage defective viruses is exposed on the virion surface
(Paredes et al., 1998), and on functional data demonstrating
that sequences at the PE2 cleavage site can interact with
surface components of the target cell (Klimstra et al.,
1999a). The Ig-binding domains were fused to E2 using a
17 amino acid linker element consisting of Arg-Ser
(contributed by a BglII restriction site) followed by
[Gly4Ser]3 (Fig. 1A). The core [Gly4Ser]3 element is
predicted to lack an ordered secondary structure and has
been used successfully to link components of single chain
antibodies and cytokines which require proper folding to
maintain function (Huston et al., 1988; Lieschke et al.,Fig. 1. Structure of PpL/E2 fusion proteins. (A) Viruses were constructed that exp
viruses designated L1, L2, L3, and L4, the B domain(s) were fused to E2 thro
designated L1LN, the first B domain of PpL was linked directly to E2. (B) Thre
domain sequence. L1 contained the wild type sequence of B domain #1. This se
residues 31–33. This signal was altered in the virus designated ND/SK by site-
designated IBN shares these mutations, and harbors three additional mutations, wh
N-linked glycosylation signal in L1 and altered sequences in ND/SK and IBN ar
binding activity of sites 1 and 2 are identified by number.1997). We reasoned that placement of this linker element
between the PpL and E2 sequences would provide
flexibility at the PpL/E2 junction, which in turn should
facilitate proper folding of E2 and the establishment of
functional interactions between E2 and E1. Three variants of
L1 were also constructed. The first variant, designated
L1LN, lacks the linker element and contains the single B
domain fused directly to E2 (Fig. 1A). The second variant,
designated ND/SK, is isogenic with L1 except for mutations
at PpL residues 31 (Asn to Asp) and 33 (Ser to Lys), which
were introduced to eliminate a potential site for N-linked
glycosylation (Fig. 1B). When expressed in bacteria, this
site would not be expected to function as a glycosylation
signal. However, when expressed in the context of a
recombinant Sindbis virus, this site could be glycosylated
during virus replication in eukaryotic cell lines and in vivo,
and carbohydrate moieties bound at this site could
potentially interfere with the Ig-binding properties of theress 1 to 4 PpL B domains (PpL-d1-4) as N-terminal extensions of E2. In
ugh a 17-amino acid linker peptide consisting of RS[G4S1]3. In the virus
e variations of the L1 virus were constructed, each containing a unique B
quence contains a single potential N-linked glycosylation signal (NGS) at
directed mutagenesis of residues 31 (N to D) and 33 (S to K). The virus
ich collectively ablate the Ig-binding activities of sites 1 and 2. The potential
e shown in bold and underlined text. Mutations in IBN that affect the Ig-
Fig. 2. Growth kinetics of parental and recombinant viruses. BHK-21 cells
were electroporated with in vitro-generated viral transcripts derived from
each cDNA clone. Electroporations were performed in duplicate for each
virus and samples of growth medium were harvested at 6-h intervals post-
electroporation. Infectious virus was quantified by standard plaque assay on
monolayers of BHK-21 cells. Virus titers were reported as the average of
values obtained for the duplicate samples.
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ND/SK except for two point mutations present within Ig-
binding site 1 (53 Tyr to Phe and 57 Leu to His), and a
single mutation in Ig-binding site 2 (66 Val to Trp) (Fig.
1B). These mutations independently ablate the Ig-binding
activities of sites 1 and 2, respectively (Housden et al.,
2004), and therefore, IBN was predicted to express the PpL
B domain 1 in a non-functional form.Fig. 3. Protein composition of parental and recombinant viruses. Virions were m
cells, and purified from growth medium by ultracentrifugation through potassium t
LSC and 100 K CPM of each sample was then resolved in SDS-polyacrylamideThe growth properties of the recombinant viruses were
evaluated in BHK-21 cells (Fig. 2). The viruses encoding a
single PpL B domain (L1, ND/SK, IBN, and L1LN) grew
with similar kinetics and achieved peak titers that were
approximately 10-fold lower than that of E2S1. These
viruses produced small plaques compared to E2S1 and
maintained this phenotype throughout the infection. Specific
infectivity (plaque forming units [pfu]/counts per minute
[CPM]) of purified, radiolabeled ND/SK and IBN virus
preparations was similar to that of E2S1 (data not shown),
suggesting that the decreased growth of these viruses
relative to E2S1 likely represented minor limitations in the
efficiency of particle formation by these PpL-containing
viruses. These results indicate that in the context of a virus
containing a single PpL B domain, elimination of the linker
sequence, the N-linked glycosylation signal, or the Ig-
binding activity, did not affect virus growth or genetic
stability. The kinetics of virion production and the peak titer
values determined for the L2, L3, and L4 viruses decreased
progressively in accordance with the increasing number of
PpL B domains encoded by these viruses. L2 maintained a
small plaque morphology throughout the 30-h infection;
however, the L3 and L4 viruses steadily reverted to a large
plaque phenotype.
Radiolabeled virions were analyzed by SDS-PAGE to
determine if the recombinant viruses incorporated PpL/E2
fusion proteins into their virion structure (Fig. 3). Compared
to the relative mobility (Mr) of native E2 (expressed by
E2S1), the Mr of the PpL/E2 fusion proteins encoded by L1,
ND/SK, IBN, and L1LN were decreased due to the
incorporation of the single PpL B domain. As predicted,
the Mr of the PpL/E2 protein expressed by L1LN was
increased slightly compared to that of L1 due to the absence
of the linker element. The subtle size difference observed
between the PpL/E2 proteins of L1 and ND/SK suggests
that the N-linked glycosylation signal in L1 is utilized when
virus is propagated in BHK-21 cells, and that the mutationsetabolically radiolabeled with [35S]-methionine during growth in BHK-21
artrate gradients as described in the text. Purified virions were quantified by
(10% acrylamide) gels and visualized by autoradiography.
Fig. 4. Immunoglobulin-binding properties of the parental and recombinant
viruses. The ELISA was performed as described in the text using ELISA
plates coated with purified viruses (100 ng/well) and biotinylated IgG
(human, mouse, or goat) or murine IgG-derived F(abV)2 fragments. The
ELISA titer was calculated as the inverse of the IgG or F(abV)2 dilution that
yielded OD450 nm readings  0.2 above background. *OD450 nm  0.2 at
lowest dilution tested (1:125 for IgG and 1:100 for F(abV)2).
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this site (Fig. 3). The Mr of the PpL/E2 protein from L2 and
L3 virions decreased in accordance with the increasing
number of PpL B domains encoded by these viruses. The L4
virion preparation appeared to contain markedly less PpL/
E2 fusion protein than the other PpL containing viruses.
This result suggested that L4 was genetically unstable, and
that PpL sequences were deleted from the virus during
replication. This observation is consistent with the poor
growth of L4 in BHK-21 cells, and its rapid reversion to a
large plaque phenotype. To address this issue further, six
large plaque variants of L4 were isolated on BHK-21 cells,
plaque purified, and sequenced across the PpL-encoding
region. Each virus contained a large in frame deletion within
the PpL sequences resulting in the complete loss of B
domains 2 and 3, and most of domains 1 and 4 (data not
shown). Based on these results, the L4 virus was not studied
further.
Recombinant viruses bind Ig in a species-specific manner
PpL binds Ig derived from many, but not all, mammalian
species (De Chaˆteau et al., 1993). For example, PpL binds
with high affinity to kappa light chain-containing Igs
derived from humans and mice, but does not bind Ig
derived from goats or sheep. To determine if fusion of PpL
B domains onto E2 conferred Ig-binding activity, virions
were grown in BHK-21 cells, purified by ultracentrifuga-
tion, and assayed for Ig-binding activity in ELISA. Results
demonstrated that recombinant viruses containing functional
B domains recapitulated the species-specific Ig-binding
phenotypes of native PpL. Specifically, each of these
viruses (L1, L2, L3, ND/SK, and L1LN), bound strongly
to polyclonal IgG from human and mouse, but bound
weakly, if at all, to polyclonal caprine IgG (Figs. 4A, B).
Binding of human and mouse IgG was specific, as IgG-
binding was not detected in wells coated with E2S1 virions,
or in wells that contained no viral antigens. Several factors
influenced the Ig-binding properties of the PpL-containing
viruses. Using the IgG-binding properties of L1 as a point of
reference, it was shown that IgG binding was modestly
enhanced by fusing additional PpL B domains onto E2 (e.g.,
L2 and L3), and by removing the N-linked glycosylation
signal in B domain 1. In addition, comparisons between the
IgG-binding properties of L1 and L1LN suggest that
placement of the linker sequence between the PpL and E2
sequences enhanced the Ig-binding properties of the virus,
albeit only slightly. The ELISA results also suggest that
virion binding to human and mouse Ig was mediated by
interactions with the VL domain of the captured Ig and the
PpL component of the virus spike. First, IBN virions, which
express a non-functional B domain, failed to bind IgG from
any species above background levels. Second, ND/SK
virions bound strongly to murine IgG-derived F(abV)2
fragments (Fig. 4C), while E2S1 and IBN virions did not.
Finally, ND/SK virions bound human IgG and human serumIgA to similar levels (data not shown). The remaining
experiments were limited to the parental virus, ND/SK,
IBN, or the green fluorescent protein (GFP)-expressing
derivatives of these viruses. ND/SK was selected as the
representative Ig-binding virus because it consistently
bound Ig better than any other virus containing a single B
Table 1
Virion binding to FcgR-positive and FcgR-negative cell lines
Virus Cell line Treatment % of added CPM
bound F SD
ND/SK Balb/3T3a No serum 0.27 F 0.04
Mouse serum 0.61 F 0.06
Goat serum 0.26 F 0.01
RAW 267.4b No serum 0.48 F 0.04
Mouse serum 10.16 F 0.50
Goat serum 0.85 F 0.16
Mouse IgG 9.17 F 0.90
F(abV)2c 0.46 F 0.12
J774A.1b No serum 1.64 F 0.19
Mouse serum 19.65 F 4.02
Goat serum 1.17 F 0.09
Rajib No serum 0.61 F 0.08
Human serum 28.35 F 3.66
Goat serum 0.64 F 0.07
IBN Balb/3T3 No serum 0.89 F 0.71
Mouse serum 0.38 F 0.04
Goat serum 0.42 F 0.04
RAW 267.4 No serum 1.95 F 0.52
Mouse serum 1.61 F 0.14
Goat serum 1.01 F 0.08
J774A.1 No serum 1.68 F 0.26
Mouse serum 1.85 F 0.35
Goat serum 1.74 F 0.12
Raji No serum 0.93 F 0.23
Human serum 0.73 F 0.06
Goat serum 0.82 F 0.12
a FcgR-negative.
b FcgR-positive.
c Derived from murine IgG.
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were less stable and replicated to lower titers than ND/SK
(Fig. 2), and displayed little or no improvement in Ig-
binding activity over that of ND/SK (Fig. 4).
Ig-bound virions display enhanced binding and ADE for
FccR-positive cells
Virions complexed with IgG through PpL should interact
with FcgRs, and therefore, are predicted to display
enhanced binding to FcgR-positive cell types. This pre-
diction was tested in cell-binding assays using purified
preparations of radiolabeled ND/SK and IBN virions.
Binding assays were performed using FcgR-positive murine
(RAW264.7 and J774A.1) and human (Raji) cell lines
(Cote-Ve´lez et al., 2001; Guglielmi and Preud’homme,
1981; Raschke et al., 1978), and a FcgR-negative murine
cell line (BALB/3T3) (Ran et al., 1988) and data not shown.
The presence or absence, respectively, of FcgRs was
confirmed for RAW 264.7 and BALB/3T3 cells using a
CD16/32-specific rat anti-mouse antibody (eBioscience;
data not shown). We have previously determined that the
binding of E2S1 to cultured cell lines such as RAW 264.7
and Raji is very low (1% of added CPM) (Klimstra et al.,
1998), and data not shown. Incubation of IBN virions with
species-matched serum or goat serum did not significantly
alter virion binding above background to any cell line
tested, and neither virus displayed appreciable binding to
BALB/3T3 cells under any conditions (Table 1). In contrast,
incubation of ND/SK virions with mouse serum markedly
enhanced virion binding to RAW 264.7 and J774A.1 cells
(21-fold and 12-fold, respectively), and incubation with
human serum enhanced virion binding to human Raji cells
46-fold (Table 1). Although not definitive, these experi-
ments suggest that the binding of Ig-complexed ND/SK
virions to RAW 264.7, J774A.1, and Raji cells was FcR-
mediated. To address this issue more directly, we compared
the effects that purified murine IgG and murine IgG-derived
F(abV)2 fragments had on ND/SK binding to RAW 264.7
cells. ND/SK virions incubated with the F(abV)2 fragments
did not bind RAW 264.7 cells above background levels;
however, incubation of virions with purified IgG resulted in
enhanced binding comparable to that achieved using non-
immune mouse serum (Table 1).
Capture of virion/Ig complexes by FcRs is a prerequisite
for FcR-mediated ADE. To determine if Ig-mediated bind-
ing of ND/SK virions to RAW 264.7 and J774A.1 cells
facilitated ADE, infection assays were performed using
GFP-expressing versions of ND/SK (ND/SK-26S/GFP) and
IBN (IBN-26S/GFP). RAW 264.7 and J774A.1 cells display
antibody-dependent phagocytosis (Arulanandam et al.,
2001; Raschke et al., 1978), but are nearly refractory to
infection by free E2S1 virus particles (data not shown).
Cells were infected by ND/SK-26S/GFP and IBN-26S/GFP
virions following incubation of virus with diluent, heat-
inactivated mouse serum, or goat serum. ND/SK-26S/GFPvirions were also incubated with purified murine IgG or
murine IgG-derived F(abV)2 fragments prior to infection of
RAW 264.7 cells. At 8 h post-infection, virus infected cells
were identified by GFP expression using fluorescence
microscopy, and GFP-expressing cells were quantified by
flow cytometry. Infection of cells by IBN-26S/GFP was not
significantly enhanced over background by murine or goat
serum (Fig. 5 and Table 2). In contrast, infection of RAW
264.7 or J774A.1 cells with ND/SK-26S/GFP virions pre-
incubated with mouse serum resulted in a marked increase
in numbers of GFP-expressing cells as compared with no
serum or goat serum controls (Fig. 5 and Table 2). Similar
results were obtained when ND/SK-26S/GFP virions were
incubated with purified murine IgG (Fig. 6 and Table 2).
Flow cytometric analysis suggests that some cells remained
uninfected under these conditions (Table 2); however,
virtually all RAW 264.7 and J774A.1 cells infected with
mouse serum- or IgG-treated ND/SK-26S/GFP virions
appeared to be GFP-positive by fluorescence microscopy
(Figs. 5 and 6). This discrepancy may reflect the large range
of GFP signal intensity expressed by different infected cells.
Incubation of ND/SK-26S/GFP virions with mouse serum
did not enhance infection of BALB/3T3 cells, which are
FcgR-negative (Table 2). Consistent with results obtained
using the FcgR-expressing cell lines, ND/SK-26S/GFP
infection of primary murine BMDCs, which have been
Fig. 5. Antibody-dependent enhancement of infection by murine serum. Monolayers of RAW 264.7 and J774A.1 cells were infected with ND/SK-26S/GFP and
IBN-26S/GFP either untreated or pre-treated with heat-inactivated mouse or goat serum as described in the text. Upper panels for each group are GFP
fluorescence images and lower panels are phase contrast bright-field images of the same field of view. Magnification = 200.
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enhanced (approximately 12-fold) by incubation with
mouse serum (Table 2).
Several distinct mechanisms for ADE have been
described. These include enhanced infection by IgG-opson-
ized virions through an FcgR-dependent pathway, andTable 2
Flow cytometric analysis of virus infected cells
Virus Cell line Treatment % GFP
positive F SDa
ND/SK BALB/3T3 No serum 0.67 F 0.10
Mouse serum 0.59 F 0.09
Goat serum 0.77 F 0.17
RAW 267.4 No serum 1.69 F 0.55
Mouse serum 76.16 F 0.53
Goat serum 3.13 F 0.57
Mouse IgG 55.32 F 2.56
Mouse IgG F(abV)2 1.97 F 0.23
J774A.1 No serum 1.85 F 0.44
Mouse serum 44.21 F 0.04
Goat serum 2.90 F 0.14
Mouse BMDC No serum 0.45 F 0.14
Mouse serum 5.30 F 0.80
Goat serum 0.92 F 0.29
IBN BALB/3T3 No serum 0.77 F 0.15
Mouse serum 0.85 F 0.13
Goat serum 0.41 F 0.05
RAW 267.4 No serum 1.48 F 0.13
Mouse serum 2.24 F 0.19
Goat serum 2.21 F 0.08
J774A.1 No serum 2.54 F 0.13
Mouse serum 2.69 F 0.68
Goat serum 3.24 F 0.05
Mouse BMDC No serum 1.49 F 0.33
Mouse serum 1.66 F 0.20
Goat serum 1.41 F 0.08
a 1.0  104 cells were analyzed for each sample. Thresholds for GFP
expression were set using mock-infected cells. Values represent an average
of two or three samples and all experiments were repeated at least twice.activation of complement by virion-containing ICs with
subsequent binding and entry through a complement recep-
tor-dependent pathway (Takada and Kawaoka, 2003). Some
monoclonal antibodies have also been shown to enhance
Sindbis virus infection via a third mechanism that is
independent of FcRs and complement receptors, and involves
antibody-induced conformational rearrangements of the
virion structure (Flynn et al., 1988). Although serum-treated,
PpL-modified virions likely bind Igs of multiple classes, the
primary mechanism of ADE demonstrated in this study is
almost certainly FcgR-dependent. First, Ig-enhanced binding
of ND/SK virions to selected cell lines correlated with
cellular expression of FcgRs. Second, ADE for RAW 264.7
cells was achieved when ND/SK-26S/GFP virions were
incubated with murine IgG, but failed to occur when virions
were incubated with murine IgG-derived F(abV)2 (Fig. 6 and
Table 2). Third, ND/SK-26S/GFP virions incubated with
heat-inactivated mouse serum or purified IgG still exhibited
ADE for RAW 264.7 and J774A.1 cells, indicating that
activated complement components did not play a role in cell
binding or infection. Finally, although ND/SK virions bound
murine IgG, human serum IgG, and human serum IgA, ADE
was only achieved on RAW 264.7 and J774A.1 cells by
virions that had been incubated with the murine serum or
purified murine IgG. If ADE under these conditions was
mediated through a virion activation mechanism, then
incubation of virions with murine IgG-derived F(abV)2 frag-
ments, human serum IgG, or human serum IgA would be
expected to facilitate ADE as well.
Viruses expressing Ig-binding domains of PpL are
attenuated in mice
The goal of developing Sindbis virus vectors that are
highly infectious when targeted to FcR-positive cells via a
ADE mechanism was achieved in this study; however, it
Fig. 6. The effect of purified IgG and IgG-derived F(abV)2 fragments on viral infection. Monolayers of RAW 264.7 cells were infected with ND/SK-26S/GFP
either untreated or pre-treated with purified mouse IgG or purified mouse IgG-derived F(abV)2 fragments as described in the text. Upper panels for each group
are GFP fluorescence images and lower panels are phase contrast bright-field images of the same field of view. Magnification = 200.
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increased disease severity caused by some viruses including
Dengue virus and Ebola virus (Takada and Kawaoka, 2003).
In addition, PpL was first identified as a bacterial virulence
determinant based on its association with an enhanced
vaginal colonization phenotype (Kastern et al., 1990; Ricci
et al., 2001). Therefore, it was important to determine if
viruses expressing PpL B domains display enhanced
virulence in vivo. To address this issue, the virulence
phenotypes of E2S1, ND/SK, and IBN were compared in
adult and neonatal CD-1 mice (Table 3). All viruses,
including the parental strain, were essentially avirulent for
adult mice, even when virus was administered intracere-
brally (i.c.). In contrast, E2S1 caused 100% mortality with
an average survival time (AST) of approximately 2 days in
newborn mice following subcutaneous (s.c.) inoculation.
IBN and ND/SK were attenuated in newborn mice
compared to E2S1 based on percent mortality and AST
values. IBN caused 83% mortality with an AST of
approximately 7.1 days, and ND/SK caused 38% mortality
with an AST of approximately 7.2 days. To address the
possibility that Ig binding contributed to the attenuated
phenotype of ND/SK, virions were pre-incubated with
purified murine IgG or with diluent for 30 min prior toTable 3
Virulence of viruses for neonatal and adult mice
Virus Neonates (12–24 h) Adults (3–4 weeks)
Subcutaneous Subcutaneous Intracerebral
% mortality ASTa % mortality AST % mortality AST
E2S1 100% (24/24) 2.0 F 0.2 0% (0/3) N/A 0% (0/3) N/A
IBN 83% (20/24) 7.1 F 1.4 0% (0/3) N/A 0% (0/3) N/A
ND/SK 38% (9/24) 7.2 F 1.5 0% (0/3) N/A 0% (0/3) N/A
CD-1 mice were infected with 103 pfu of each virus and observed daily for
signs of morbidity or mortality for 21 days post-infection.
a Average survival time (days) FSD.being administered (s.c.) to newborn mice (36 mice/group).
Diluent-incubated preparations produced 42% mortality
(AST 6.3 F 2.3 days), whereas only 17% of the mice
succumbed to infection by IgG-incubated virions (AST 6.4F
1.9 days). Together, the results of these experiments
demonstrate that incorporation of a PpL B domain into the
Sindbis virus particle attenuates virulence in vivo and suggest
that Ig binding contributes to this phenotype.
The precise mechanism(s) by which PpL enhances
bacterial virulence is poorly characterized, but presumably
is related to Ig-related effector functions that are activated
upon ligand binding. For example, antigen-bound IgG and
IgM can activate the classical complement cascade, and
antigen binding or cross-linking of Ig expressed on cell
surfaces (i.e., on surface of B lymphocytes, mast cells/
basophils) can induce cellular changes ranging from cellular
activation to apoptosis (Ravetch and Bolland, 2001).
Therefore, the ability of PpL to bind Ig in a class- and
antigen-independent manner raises the possibility that
vaccines incorporating one or more B domain of PpL could
induce inflammatory responses and/or polyclonal B cell
activation or deletion as a consequence of cross-linking IgE
on mast cells/basophils, or Igs expressed on B lymphocytes,
respectively. PpL can cross-link IgE on the surface of
human basophils and mast cells grown in cell culture,
leading to the release of proinflammatory mediators (e.g.,
histamine), and immunoregulatory cytokines (e.g., IL-4 and
IL-13) (Genovese et al., 2000, 2003; Patella et al., 1990).
When added to a human B lymphocyte-derived cell line,
PpL induced a polyclonal down-modulation of B cell
receptors (Viau et al., 2004), and when administered to
mice at a peripheral site, PpL localized within B cells and
DCs in secondary lymphoid tissues (Goodyear et al., 2004;
Smith et al., 2004), and induced apoptotic supraclonal
deletion of B cells within these sites (Goodyear et al., 2004).
These in vitro and in vivo studies used killed P. magnus
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contained multiple B domains. The biological effects of PpL
on mast cells/basophils and B lymphocytes that were
observed in these studies were dose-dependent and it is
not known whether PpL-containing viruses would induce
similar biological effects in vivo. Although our results
indicate that Sindbis virus vectors containing a single
functional PpL B domain were attenuated in newborn mice,
additional studies will need to be performed to determine if
these viruses induce pathological features different from
those induced by unmodified virus. If PpL-containing
alphaviruses displayed an unacceptable enhancement of
virulence/pathogenesis due to ADE, the problem may be
addressed by designing the vectors as replication-defective
replicons, which could not spread beyond the originally
infected FcR-positive target cell.
Implications of PpL-containing vectors for vaccine design
Based on immunological considerations, enhancing the
tropism of vaccines for immunologically relevant cell
types/tissues should improve vaccine efficacy, and efforts
to improve alphavirus-based vaccine vectors along these
lines have been described (Gardner et al., 2000; Klimstra
et al., 2003). In general, antigen-dependent stimulation of
naive lymphocytes and their subsequent differentiation into
effector and memory subsets occurs within secondary
lymphoid tissues (e.g., lymph nodes, spleen, Peyer’s
patches etc.), and the most effective immune responses
are mounted against antigens that are efficiently delivered
or expressed at these sites. In addition, the magnitude,
quality, and anamnestic properties of adaptive immune
responses are profoundly influenced by the participation of
DCs in antigen processing and presentation (Banchereau
and Steinman, 1998; Steinman and Pope, 2002). One
strategy for enhancing interactions between vaccine anti-
gens/vectors and DCs is to target the antigen/vector to
specific receptors on the DC surface by modifying the
viral receptor-binding proteins. For example, Sindbis
virions propagated under conditions that limit the process-
ing of viral glycoprotein-linked carbohydrate groups to
high mannose structures displayed a markedly enhanced
tropism for DCs due to improved interactions with the C-
type lectins DC-SIGN and L-SIGN (Klimstra et al., 2003).
It is reasonable to speculate that PpL-containing alphavi-
ruses based on the design of ND/SK would form ICs with
existing IgG in vivo following administration at a
peripheral site, and that the resulting ICs would be bound
and internalized by DCs and other FcgR-positive cell
types. Internalization of ICs by DCs should lead to DC
activation and migration to regional secondary lymphoid
tissues and subsequent antigen expression/presentation at
these important immune inductive sites. Sindbis virus can
infect DCs in culture and in vivo (Gardner et al., 2000;
Klimstra et al., 2003; Ryman et al., 2000, 2002), and
infection should result in the efficient presentation ofpeptides derived from virus-expressed antigens to Th cells
in the context of MHC I proteins.
This study focused specifically on applying the PpL
approach to targeting alphavirus-based vectors to FcR-
positive cell types; however, it should be possible to employ
this approach to target other vectors (e.g., adenoviruses,
parvoviruses, retroviruses, poxviruses, etc.) as well. In
addition, it may also be possible to use PpL B domains to
target free vaccine antigens, or vector-expressed antigens to
DCs in vivo using a similar approach. When expressed in
vivo, the fusion proteins should form ICs with circulating
Ig, which in turn should be bound and internalized by FcR-
positive cells such as DCs. Targeting vaccine antigens to
DCs via the FcgR-mediated pathway may be a particularly
effective means of inducing antigen-specific CTL responses.
DCs that bind and internalize antigens via the FcgR-
mediated pathway are able to process and present antigens
in the context of MHC class I molecules (Amigorena, 2002;
Gil-Torregrosa et al., 2004; Guermonprez et al., 2002;
Machy et al., 2000; Regnault et al., 1999; Schuurhuis et al.,
2002). This process, called cross-presentation, is thought to
be necessary, if not essential, to the induction of most CTL
responses (Lize´e et al., 2003), and IC-mediated delivery of
antigens to DCs via FcR interactions is a promising strategy
for inducing CTL-specific immunity to intracellular patho-
gens and tumors (Dhodapkar et al., 2002; Kalergis and
Ravetch, 2002; Moore et al., 2003; Rafiq et al., 2002).Materials and methods
Cells and growth conditions
BHK-21 cells were maintained in alpha minimum
essential medium (MEM) supplemented with 10% donor
calf serum (DCS) and 10% tryptose phosphate broth (TPB).
J774A.1 and RAW 264.7 murine monocyte–macrophage
cell lines were maintained in Dulbecco’s modified eagles
medium (DMEM; Mediatech, Herndon, VA) supplemented
with 10% fetal bovine serum (FBS). Raji human B cells
were maintained in RPMI medium (Mediatech) supple-
mented with 10% FBS. BALB/3T3 cells were maintained in
MEM supplemented with 10% FBS. Bone marrow-derived
dendritic cell (BMDC) cultures were generated and main-
tained in RPMI medium supplemented with 10% FBS, 1%
nonessential amino acids, 1 mM sodium pyruvate, 5 mM
HEPES buffer, 50 AM h-mercaptoethanol, 10 ng/ml
granulocyte–macrophage colony stimulating factor, and
10 ng/ml interleukin 4 (Peprotech, Rocky Hill, NJ). All
medium contained antibiotics.
Construction of recombinant viruses
The parental virus used in this study is designated E2S1
(Heidner and Johnston, 1994), and all PpL-containing
viruses were constructed in the genetic background of this
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residue 528 and Val for Ala at E1 residue 72) compared to
the consensus AR339 virus (McKnight et al., 1996), neither
of which is associated with any known phenotype in cell
culture or in vivo (Klimstra et al., 1998, 1999b). Nucleotide
sequences generating a 5V-terminal BglII restriction site and
encoding a 15-amino acid linker segment ([Gly4Ser]3)
(Huston et al., 1988) were inserted between the E3 and
E2 genes in the cDNA clone of E2S1 (pTRSB-E2S1) using
an overlapping PCR cloning strategy (Thomas et al., 2003).
The resulting plasmid was designated pTRSB-E2S1-linker.
Sequences encoding 1 to 4 PpL B domains derived from
Peptostreptococcus magnus strain 312 (Kastern et al., 1992)
(GenBank accession #M86697) were amplified by PCR
using the pHDB1-4 plasmid as template (Affitech AS, Oslo,
Norway) and fused in frame and downstream of E3
sequences using the same overlapping PCR technique.
The oligonucleotides used in these reactions generated a
3V-terminal BglII restriction site immediately downstream of
the protein L sequences and amplified a product that
extended upstream of the unique AatII restriction site
present within the capsid gene sequences. The amplicons
were digested with AatII and BglII restriction enzymes and
inserted into pTRSB-E2S1-linker from which a correspond-
ing fragment had been removed. The resulting constructs
were designated pTRSB-E2S1-L1, pTRSB-E2S1-L2,
pTRSB-E2S1-L3, and pTRSB-E2S1-L4, and viruses
derived from these constructs were designated L1, L2, L3,
and L4, respectively. The first B domain of PpL encodes a
potential site for N-linked glycosylation (Asn-Gly-Ser) at
residues 31–33 (numbering according to (Graille et al.,
2001)). B domains 2–4 encode Asp-Gly-Lys at the
comparable positions (Kastern et al., 1992). The Asn-Gly-
Ser sequence was mutated to Asp-Gly-Lys using a PCR-
based mutagenesis procedure. The resulting construct was
designated pTRSB-E2S1-ND/SK, and virus derived from
this plasmid was designated ND/SK. A variant of ND/SK
was also constructed which was predicted to lack Ig-binding
activity due to placement of mutations within Ig-binding
sites 1 and 2 (Housden et al., 2004). The Ig-binding activity
of site 1 was ablated by mutating residue 53 (Tyr to Phe)
and residue 57 (Leu to His), and the Ig-binding activity of
site 2 was ablated by mutating residue 66 (Val to Trp) using
a PCR-based mutagenesis procedure. The resulting con-
struct was designated pTRSB-E2S1-IBN (immunoglobulin-
binding negative), and the virus derived from this plasmid
was designated IBN. Finally, sequences encoding the wild-
type B domain 1 were inserted downstream of E3 and fused
directly to E2 (without the intervening linker sequence)
using an overlapping PCR strategy. The amplicon produced
in the final overlapping PCR reaction (containing the in
frame contiguous sequences of capsid-E3-L1-E2) was
digested with AatII (in capsid sequence) and BssHII (in
E2 sequence), and inserted into pTRSB-E2S1 from which a
corresponding fragment had been removed. The resulting
construct was designated pTRSB-E2S1-L1LN (L1 linkernegative) and virus derived from this plasmid was desig-
nated L1LN.
The ND/SK and IBN viruses were further modified to
express the GFP from a duplicated 26S promoter placed into
the 3V non-translated region of the viral genome. GFP-
expressing versions of ND/SK and IBN were generated by
transferring an AatII/BssHII fragment from pTRSB-E2S1-
ND/SK and pTRSB-E2S1-IBN, respectively, into pTRSB-
E2S1-26S/GFP (Ryman et al., 2004) from which a
corresponding fragment had been removed. The resulting
viruses were designated ND/SK-26S/GFP, and IBN-26S/
GFP, respectively. All sequences that were generated and/or
amplified by PCR during cloning procedures were con-
firmed by sequence analysis (Davis Sequencing, Davis,
CA). Infectious virus was derived from each cDNA clone as
described previously (Heidner et al., 1994).
Virus growth in BHK-21 cells
The kinetics of virus growth was determined for selected
viruses in BHK-21 cells. Cells were electroporated with in
vitro-generated viral transcripts as described (Heidner et al.,
1994). Electroporations were performed in duplicate for
each virus and samples of growth medium were harvested at
6-h intervals post-electroporation. Infectious virus was
quantified by plaque assay on monolayers of BHK-21 cells.
Virus titers were reported as the average of values obtained
for the duplicate samples.
Analysis of radiolabelled virions
Virions were metabolically radiolabeled with [35S]-
methionine during growth in BHK-21 cells, and purified
from culture supernatants essentially as described (Boehme
et al., 2000; Heidner et al., 1994). Purified virions were
quantified by liquid scintillation counting (LSC), and each
virus preparation (100K CPM) was then resolved in SDS-
polyacrylamide (10% acrylamide) gels and visualized by
autoradiography.
Analysis of virion immunoglobulin binding properties
Virions were purified from infected BHK-21 cell super-
natants as described (Boehme et al., 2000). ELISA plates
(NUNC Maxisorp, Rochester, NY) were coated with
purified virions (100 ng/well), blocked with 3% bovine
serum albumin in PBS (PBS-BSA), and then probed with
biotinylated murine IgG-derived F(abV)2 fragments (Jackson
Immunoresearch Laboratories, Baltimore, MD) or biotiny-
lated Ig (mouse IgG, human IgG, or goat IgG, Vector
Laboratories, Burlingame, CA). IgG/F(abV)2 fragments were
processed in a serial 2-fold dilution series starting at a 1:100
dilution of a F(abV)2 stock (4.6 mg/ml), or a 1:125 dilution of
IgG stock in PBS-BSA (concentrations of IgG stocks were 5
mg/ml [human and goat], or 1 mg/ml [mouse]). Wells were
then probed with streptavidin–horseradish peroxidase
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substrate (o-phenylenediamine dihydrochloride). Optical
density (OD450 nm) was measured 15 min later. The ELISA
titer was calculated as the inverse of the F(abV)2 or IgG
dilution that yielded OD450 nm readings  0.2 above
background.
Cell-binding assays
Production of radiolabeled virus for cellular attachment
assays was performed essentially as described above with
the following modifications: (i) [35S]-methionine and [35S]-
cysteine were added at 8 h post-infection to a total
concentration of 40 ACi/ml; (ii) radiolabeled viruses were
purified on a 20%–60% discontinuous sucrose gradient
followed by pelleting through 20% sucrose (all in TNE);
and (iii) virus pellets were resuspended in HEPES-buffered
OptiMEM medium (Invitrogen, Carlsbad, CA). Suspension
cells (Raji) were pelleted by centrifugation and resuspended
at a concentration of 1  106 cells per 25 Al of diluent.
Adherent cells were scraped to dislodge (RAW 264.7,
J774A.1) or treated with enzyme-free cell dissociation
buffer (Invitrogen, Carlsbad, CA) (BALB/3T3), pelleted
by centrifugation and resuspended as above. Gradient-
purified, radiolabeled ND/SK or IBN virus (5  104–1 
105 CPM) was added to the cells in 50 Al total in a 96-well
V-bottom plate (Sarstedt, Newton, NC) and incubated for
1 h at 4 8C with gentle agitation. Radiolabeled viruses
were either untreated or treated for 30 min at 4 8C with
virus diluent or a 1:1250 dilution of either non-immune
goat serum, human serum, mouse serum (Sigma-Aldrich,
St. Louis, MO), purified mouse IgG or purified mouse
IgG-derived F(abV)2 fragments (Jackson Immunoresearch
Laboratories, West Grove, PA.). After incubation, cells
were washed 3  with diluent and resuspended in 100 Al
0.6% IGEPAL CA-630 (Sigma-Aldrich, St. Louis, MO)
in TNE. Radioactivity was quantitated by LSC of 50% of
the resuspended cells.
Infectivity assays
Stocks of ND/SK-26S/GFP and IBN-26S/GFP viruses,
minimally diluted to yield equivalent BHK pfu, were treated
with diluent, with a 1:1250 dilution of heat-inactivated
species-matched (mouse or human) serum or goat serum or
with a 1:1250 dilution of purified mouse IgG or IgG-derived
F(abV)2 fragments for 30 min at 4 8C prior to infection of
cells. Suspension-grown mouse BMDC were pelleted and
resuspended at a concentration of 1  106 in 25 Al virus
diluent buffer in a V-bottom plate. Treated viruses (25 Al )
were then added to the cells. Adherent cells (J774A.1, RAW
264.7, BALB/3T3, and primary BMDC) were grown in 24-
well plates and incubated with 200 Al of each virus/Ig
preparation. Cells were infected for 1 h at 4 8C and then
washed 3 with diluent. Washed cells were then maintained
in growth medium at 37 8C. At 8–12 h post infection, cellswere photographed on a Nikon TE300 fluorescence micro-
scope using an Endow GFP filter. The remainder of each
sample was then harvested, fixed with 4% paraformalde-
hyde, and analyzed (1  104 cells scanned per reaction) for
percentage expressing GFP on a Becton-Dickinson Facscan
flow cytometer using FITC filters.
Virulence of viruses in adult and newborn mice
Adult (3–4 weeks of age) CD-1 mice (Charles River)
were infected with 103 pfu of E2S1, ND/SK or IBN viruses
by s.c. (50 Al inoculum) or i.c (10 Al inoculum) routes.
Neonatal (12–24 h old) CD-1 mice were infected s.c. (50 Al
inoculum). Mice were monitored daily for 21 days at which
time AST and percentage mortality values were calculated.
Mice were housed in the Animal Resources Center animal
facility at Louisiana State University Health Sciences
Center, Shreveport under specific pathogen-free conditions.Acknowledgments
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